Results 171 to 180 of about 1,053,264 (360)

Anemia and growth

open access: yesIndian Journal of Endocrinology and Metabolism, 2014
Ashraf T Soliman   +2 more
openaire   +4 more sources

American College of Rheumatology Guidance Statement for Diagnosis and Management of VEXAS Developed by the International VEXAS Working Group Expert Panel

open access: yesArthritis &Rheumatology, EarlyView.
Objective Vacuoles E1 enzyme X‐linked autoinflammatory somatic syndrome (VEXAS) is a recently identified rare genetic disorder associated with somatic mutations in the UBA1 gene. VEXAS presents with a combination of inflammatory and hematologic manifestations, leading to increased morbidity and mortality.
Arsene Mekinian   +111 more
wiley   +1 more source

B cells and systemic sclerosis interstitial lung disease

open access: yesArthritis &Rheumatology, Accepted Article.
Interstitial lung disease is an important complication of systemic sclerosis (SSc‐ILD) with high mortality and morbidity. Recent clinical studies in SSc‐ILD have led to FDA‐approved therapies in SSc‐ILD. Importantly, evidence from these studies has been extrapolated to guide management of interstitial lung diseases of other systemic autoimmune ...
Nina Goldman   +2 more
wiley   +1 more source

The Effect of Iron Deficiency Anemia on the Morphology-Voltage-P Wave Duration (MVP) Risk Score. [PDF]

open access: yesAnn Noninvasive Electrocardiol
Yildiz G   +4 more
europepmc   +1 more source

Comparative efficacy and safety of anakinra and canakinumab in patients with VEXAS syndrome – an international multicenter study

open access: yesArthritis &Rheumatology, Accepted Article.
Objectives The aim of this study was to compare differences in clinical response, drug survival, and adverse event rates between anakinra and canakinumab in VEXAS syndrome. Methods This multicenter international study includes VEXAS patients from France, Israel, and Italy treated with IL1 inhibition (IL1i).
Tali Eviatar   +35 more
wiley   +1 more source

Pharmacokinetics, pharmacodynamics and safety of casdatifan, a novel hypoxia‐inducible factor‐2α inhibitor, in healthy participants

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Casdatifan is an orally bioavailable small‐molecule hypoxia‐inducible factor‐2α (HIF‐2α) inhibitor currently in development for treating patients with clear cell renal cell carcinomas. The aim of this study was to characterize the pharmacokinetics (PK), pharmacodynamics and safety of casdatifan in healthy participants.
Mohammad Ghasemi   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy